This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Omura-Minamisawa, M. Articles by Yu, A. L. Search for Related Content PubMed PubMed Citation Articles by Omura-Minamisawa, M. Articles by Yu, A. L.

p16/p14^ARF Cell Cycle Regulatory Pathways in Primary Neuroblastoma

p16 Expression Is Associated with Advanced Stage Disease¹

Department of Pediatrics/Hematology-Oncology, University of California, San Diego, California 92103 [M. O-M., M. B. D., R. C. C., A. B., L. J. B., J. S., A. L. Y.]; Department of Pediatrics, Northwestern University and Children’s Memorial Hospital, Chicago, Illinois 60614 [S. L. C.]; and Pediatric Oncology Group, University of Florida, Gainesville, Florida 32601 [W. B. L.]

p16 regulates the G₁-S cell cycle transition by inhibiting the cyclin D-cyclin-dependent kinase (CDK)4/CDK6-mediated phosphorylation of retinoblastoma protein (pRb). We examined the possible derangement of the p16-CDK/cyclin D-pRb pathway in 40 primary neuroblastomas including 18 samples in the unfavorable stages (C and D) and 22 in the favorable stages (A, B, and Ds) by PCR, reverse transcription-PCR, Western blot, and immunohistochemistry and correlated the results with clinical outcome. No samples harbored alterations of the p16 gene. Interestingly, the samples in the unfavorable stages exhibited expression of p16 mRNA and protein more frequently than those in the favorable stages [mRNA, 9 of 18 (50%) versus 2 of 22 (9%), P = 0.006; protein, 5 of 16 (31%) versus 0 of 18 (0%), P = 0.013]. Alterations of the downstream components of the pathway were infrequent. pRb was deregulated in the majority of samples investigated [27 of 33 (82%), 24 with hyperphosphorylated pRb and 3 with no pRb protein]. The phosphorylation status of pRb did not correlate with p16 protein expression, suggesting that the elevated p16 protein may not be functioning properly to regulate the pathway. Among patients of all stages, p16 expression was significantly associated with a lower overall survival. There was no overexpression of MDM2, and loss of p14^ARF expression and p53 mutation were infrequent events. Taken together, these findings suggest that up-regulated p16 expression may represent a unique feature of aggressive neuroblastoma.

This article has been cited by other articles:

				J. Carr, E. Bell, A. D.J. Pearson, U. R. Kees, H. Beris, J. Lunec, and D. A. Tweddle Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse Cancer Res., February 15, 2006; 66(4): 2138 - 2145. [Abstract] [Full Text] [PDF]

				Q. Wang, G. Hii, S. Shusterman, Y. Mosse, C. L. Winter, C. Guo, H. Zhao, E. Rappaport, M. D. Hogarty, and J. M. Maris ID2 Expression Is not Associated with MYCN Amplification or Expression in Human Neuroblastomas Cancer Res., April 1, 2003; 63(7): 1631 - 1635. [Abstract] [Full Text] [PDF]